Tango Therapeutics, Inc.
TNGX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001819133
In the last 90 days, Tango Therapeutics, Inc. insiders filed 0 open-market purchases and 4 sales; 247 institutions reported holding it in 13F filings for Q2 2026, worth $6.63B in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $2.34M in total
- 4
- 13F holdersQ2 2026, +55 vs. previous quarter
- 247
- 13F valueReported value at the end of Q2 2026
- $6.63B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding TNGX, Q2 2026
No superinvestor reported holding TNGX at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Tango Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 24, 2026 (view filing)7:41 PM ET | Sep 22 | 2 days | Newcomb JessicaPrincipal Accounting Officer | SSale | −8.20K | $24.22 | −$198.6K | −12.2%59.1K after | 3 lots10b5-1 |
| Sep 3, 2026 (view filing)4:01 PM ET | Sep 1 | 2 days | Crystal AdamPresident, R&D | SSale | −27.0K | $22.37 | −$603.9K | −18.9%115.7K after | 10b5-1 |
| Aug 5, 2026 (view filing)4:01 PM ET | Aug 3 | 2 days | Crystal AdamPresident, R&D | SSale | −27.0K | $27.24 | −$735.5K | −18.9%115.7K after | 2 lots10b5-1 |
| Jul 2, 2026 (view filing)7:23 PM ET | Jul 1 | 1 day | Crystal AdamPresident, R&D | SSale | −27.0K | $29.59 | −$798.9K | −18.9%115.7K after | 2 lots10b5-1 |
| Jun 3, 2026 (view filing) | Jun 1 | 2 days | Crystal AdamPresident, R&D | SSale | −27.0K | $22.88 | −$617.6K | −18.9%115.7K after | 2 lots10b5-1 |
| May 5, 2026 (view filing) | May 1 | 4 days | Crystal AdamPresident, R&D | SSale | −27.0K | $21.22 | −$573.0K | −18.9%115.7K after | 2 lots10b5-1 |
| Apr 16, 2026 (view filing) | Apr 15 | 1 day | Crystal AdamPresident, R&D | SSale | −38.5K | $25.00 | −$961.5K | −25.5%112.6K after | 10b5-1 |
| Apr 2, 2026 (view filing) | Apr 1 | 1 day | Crystal AdamPresident, R&D | SSale | −27.0K | $21.20 | −$572.4K | −19.3%112.6K after | 10b5-1 |
| Mar 27, 2026 (view filing) | Mar 25 | 2 days | Crystal AdamPresident, R&D | SSale | −12.0K | $20.11 | −$241.3K | −9.6%112.6K after | 10b5-1 |
| Mar 9, 2026 (view filing) | Mar 5 | 4 days | Crystal AdamPresident, R&D | SSale | −20.3K | $15.00 | −$303.8K | −15.2%112.6K after | 10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in Tango Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| RTW Investments, LP | 13,900,620 | $434.5M | 3.71% | +600,000+4.5% | Added |
| BlackRock, Inc. | 12,438,444 | $388.8M | 0.01% | +3,690,399+42.2% | Added |
| FMR LLC | 12,333,339 | $385.5M | 0.02% | +2,427,420+24.5% | Added |
| Farallon Capital Management, L.L.C. | 12,277,000 | $383.8M | 2.25% | +3,179,589+35.0% | Added |
| Boxer Capital Management, LLC | 10,876,219 | $340.0M | 25.61% | 00.0% | Unchanged |
| Goldman Sachs Group Inc | 9,980,620 | $312.0M | 0.03% | +4,904,228+96.6% | Added |
| TCG Crossover Management, LLC | 9,081,201 | $283.9M | 6.82% | −1,449,870−13.8% | Reduced |
| Paradigm Biocapital Advisors LP | 6,357,523 | $198.7M | 3.72% | +2,347,844+58.6% | Added |
| Price T Rowe Associates Inc | 6,348,827 | $198.5M | 0.02% | +5,459,427+613.8% | Added |
| Siren, L.L.C. | 6,179,364 | $193.2M | 3.92% | +522,259+9.2% | Added |